Promising combo for tough lymphoma cases never gets off the ground
NCT ID NCT06767956
First seen Apr 23, 2026 · Last updated May 09, 2026 · Updated 2 times
Summary
This study planned to test a combination of two drugs, golcadomide and nivolumab, in adults with non-Hodgkin lymphoma that continued to grow or came back after CAR-T cell therapy. The goal was to find the safest dose and see if the combo could shrink tumors. However, the trial was withdrawn before any patients were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.